Home > Research > Scientific Programmes: Clinical Research Programme > H12O-CNIO Lung Cancer Clinical Research Unit

Clinical Research Programme

H12O-CNIO Lung Cancer Clinical Research Unit

Head of Unit:  Luis Gonzaga Paz-Ares
Overview

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Our Unit is dedicated to the study of lung cancer, combining basic research studies with other more clinically oriented research studies, closer to solving the problems of lung cancer patients. The two main research areas of our Unit include: the identification of new molecular biomarkers that can be used in the clinic for diagnostic, prognostic and predictive purposes; and the development of novel treatment strategies that include targeted therapies and immunotherapeutics. For example, we have elucidated the molecular determinants of the oncogenicity of FGFRs, and have discovered biomarkers to monitor the efficacy of FGFR inhibitors in lung cancer. On the other hand, we have developed a patient-derived xenograft (PDX) platform of non-small-cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in bringing new drugs to the clinic (phase I trials), as well as in conducting practice-changing phase II/III trials in the fields of precision oncology and immuno-oncology.